

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

NCT06952517

Status	RECRUITING
Phase	Phase 2
Sponsor	Narrows Institute for Biomedical Research
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (5)

- Men and women ages 18+.
- Diagnosis of rosacea type 2 (papulopustular).
- Available and willing to comply with study instructions and attend all study visits.
- Able and willing to provide written and verbal informed consent.
- Subject has used the same type and brand of make-up, other facial products, and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the baseline visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion (9)

- Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
- Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
- Pregnant, lactating, or is planning to become pregnant during the study.
- Subject is currently enrolled in an investigational drug or device study.
- Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline).

... and 4 more (see full listing online)

Locations (1 total)

New York Harbor VA Brooklyn Campus, Brooklyn, New York, United States